Advanced Search

 

Study ID Status Title Patient Level Data
FFR20002 Completed A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the effect of fluticasone furoate aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
FFR30002 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Perennial Allergic Rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
FFR30003 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR30006 Completed A 4 week randomized, double blind, placebo controlled study of GW685698X Aq nasal spray 100mcg QD in adults and adolescents with Vasomotor Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR30007 Completed A 4 week randomized, double blind, placebo controlled study of GW685698X Aq nasal spray 100mcg QD in adults and adolescents with Vasomotor Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR30008 Completed A two week randomized, double blind placebo controlled, parallel group study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in pediatric subjects with Perennial Allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU105924 Completed A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU105927 Completed A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU108556 Completed A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject with Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU109045 Completed A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU109047 Completed A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU111439 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
FLD40001 Completed A randomised double-blind, active-controlled study to compare the systemic effects of fluticasone propionate ointment 0.005%, mometasone furoate ointment 0.1% and placebo ointment applied under occlusion for 5 days in healthy volunteers
FLD40002 Completed A Comparative evaluation of the atrophogenic potential of fluticasone propionate ointment 0.005%, mometasone furoate ointment 0.1% and hydrocortisone ointment 1% in healthy volunteers.
FLIC06 Completed Inhaled Fluticasone Propionate in Asthmatic children. A multicentre, double-blind, double dummy, parallel group study to compare the efficacy and tolerability of inhaled fluticasone propionate 50mcg bid via metered dose inhaler (MDI) with sodium cromoglycate (DSCG) 10mg qds via metered dose inha ...
FLIC09 Completed Nebulised Fluticasone propionate in an upper respiratory tract inflammatory disorder (rhinopharyngitis): a multicentre, randomised, blinded, parallel group study of the efficacy and safety of nebulised fluticasone propionate 0.5mg daily compared with nebulised beclomethasone dipropionate 0.8mg d ...
FLIC12 Completed A multicentre, blinded, parallel group, randomized study to compare the efficacy and tolerability of nebulised Fluticasone propionate 0.25mg administered twice daily versus nebulised Budesonide 0.5mg administered twice daily in children with mild asthma.
FLIC15 Completed A multicenter, randomised, double-blind, parallel group study of the efficacy of fluticasone propionate (FP) diskus 100mcg/bid or 500mcg/bid to induce variations of eosinophils and of Eosinophil Cationic Protein (ECP) in serum and in sputum and to induce variations of exhaling nitric oxide (NO) ...
FLIC16 Completed A multicentre, randomised, double-blinded, parallel-group comparison of the efficacy and tolerability of fluticasone propionate 100mcg bid with nedocromil MDI 4mg bid in mild-moderate asthmatic children
FLIP01 Completed Inhaled Fluticasone Propionate for the Treatment of Moderately Severe Asthma in Patients Not Already Taking Inhaled Steroids. A Dose-Ranging Study and Comparison with Inhaled Beclomethasone Dipropionate.
FLIT 72 Completed A Multicentre, Randomised, Double-Blind, Parallel Group, Six-Week Study To Compare The Efficacy and Safety of Fluticasone Propionate 500?g Daily via the Pressurised Inhaler and via the Diskhaler™ Inhaler with Beclomethasone Dipropionate 1000?g Daily via the Pressurised Inhaler in Patients with M ...
FLIT 72_1 Completed A multicentre, randomised, double-blind, parallel group, six-week study to compare the efficacy and safety of fluticasone propionate 500mcg daily via the metered dose inhaler and via the Diskhaler inhaler with beclomethasone dipropionate 1000mcg daily via the metered dose inhaler followed by a 4 ...
FLIT94/004V2 Completed A multicentre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of fluticasone propionate 500 µg bd administered by pressurised inhaler propelled by a mixture of propellants 11/12 or by an alternative propellant GR106642X for a period of three months in adu ...
FLIT94/030 Completed A multicentre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of fluticasone propionate 500 mcg bd administered by pressurised inhaler propelled by a mixture of propellants 11/12 or by an…
FLIT98 Completed Inhaled fluticasone propionate in an acute exacerbation of chronic obstructive pulmonary disease: a multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 2000 µg daily compared with placebo in chronic obstructive pulmonary dise ...

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.